Clinical Trial Update: A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2 trial update for BMS-986263 in adults with advanced hepatic fibrosis after curing hepatitis C; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Cirrhosis
• Liver Fibrosis

Drugs mentioned

• BMS-986263

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatic Cirrhosis, Liver Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2022-02-04